The addition of paclitaxel to anthracycline-based adjuvant chemotherapy significantly improves relapse-free survival (RFS) in patients with operable breast cancer, according to a new study.

[71] The trial tested the non-inferiority of capecitabine as compared with standard adjuvant chemotherapy cyclophosphamide, methotrexate and fluorouracil (CMF) or doxorubicin and cyclophosphamide ...

The use of adjuvant chemotherapy significantly lowers the risk of relapse and death in patients with operable breast cancer, and anthracycline-based regimens provide a small but significant ...